NYMOX PHARMACEUTICAL CORP (NYMX) 0.38 +0.01 (+2.7%)
0.38 +0.01 (+2.7%)
BSP733981026 - Common Stock
NYMOX Provides Current Update
IRVINE, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on business...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a breakdown of the biggest pre-market stock movers investors will want to watch on Tuesday!
NYMOX Updates Shareholders
IRVINE, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced an update to its shareholders regarding...
NYMOX Receives Deficiency Letter from NASDAQ
IRVINE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports that on July 7, 2022 the Company received a...
NYMOX Receives RTF letter from FDA
IRVINE, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that it has received a Refusal to File...
Friday 5/6 Insider Buying Report: ALGN, NYMX
Nymox Announces Closing of $6.4 Million Financing
IRVINE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has...
Nymox Announces $5 Million Registered Direct Offering
IRVINE, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive...
NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate
IRVINE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that it...